CareDx Beats on Q3 Revenue of $139M and Lifts FY26 Revenue Guidance to $520M-$530M
CDNA has more than doubled off its 52-week low of $14.225.
Summary
CareDx reported Q3 2026 revenue of $139 million (+39% year-over-year) and Adjusted EBITDA of $30 million, then raised full-year revenue guidance to $520-$530 million and Adjusted EBITDA guidance to $90-$100 million.
Key Events · Earnings and Guidance · CDNA
-
Q3 Revenue Up 39% to $139M
Total revenue was $139.4 million versus $100.1 million a year ago; Testing Services revenue rose 65% to $119.2 million and Patient and Digital Solutions rose 31% to $20.2 million.
-
FY26 Guidance Raised Sharply
Full-year 2026 revenue guidance moves to $520-$530 million from $490-$500 million, and Adjusted EBITDA guidance to $90-$100 million from $66-$78 million — a roughly 32% increase at the midpoint ($95M vs $72M).
-
Profitability Inflected
GAAP net income was $19.3 million ($0.35 diluted) versus $1.7 million a year ago, and Adjusted EBITDA was $30.5 million (22% margin) versus $15.3 million (15% margin).
-
Prior-Period Catch-Up Inflates Growth
Testing Services revenue includes $15 million recognized for tests performed in prior periods versus $6 million a year ago; excluding that, Testing Services revenue grew about 58%.
Analysis · CDNA · Industrial Applications And Services
The headline surprise is the EBITDA raise: CareDx lifted full-year Adjusted EBITDA guidance to $90-$100 million from $66-$78 million, putting the new midpoint of $95 million roughly 32% above the old midpoint of $72 million and implying management expects this quarter's margin expansion to hold. Revenue guidance moved to $520-$530 million from $490-$500 million. Third-quarter revenue grew 39% to $139 million, and Adjusted EBITDA more than doubled to $30 million. Testing Services revenue of $119 million, up 65%, includes $12 million from the Naveris/NavDx specialty oncology business acquired July 1, 2026, and $15 million of prior-period revenue recognition versus $6 million a year ago — so the underlying growth rate excluding prior-period catch-up is about 58%. With cash and equivalents of $250.5 million and $12.7 million of quarterly operating cash flow, this is a profitable-growth story rather than a financing one.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CDNA was trading at $80.04 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $14.23 to $73.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.